Clinical Trials Logo

Keratoconjunctivitis Sicca clinical trials

View clinical trials related to Keratoconjunctivitis Sicca.

Filter by:

NCT ID: NCT06329791 Not yet recruiting - Dry Eye Disease Clinical Trials

A Randomized Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Start date: May 2024
Phase: Phase 3
Study type: Interventional

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5% ophthalmic ointment or its vehicle. Study drug (either AZR-MD-001 or vehicle) will be dosed twice-weekly at bedtime for up to 12 months.

NCT ID: NCT06329687 Active, not recruiting - Dry Eye Clinical Trials

A Phase 4 Study Evaluating the Safety of the Nasal Pump

Start date: February 21, 2024
Phase: Phase 4
Study type: Interventional

The objective of this study is to determine the safety of the Tyrvaya nasal pump.

NCT ID: NCT06329661 Not yet recruiting - Dry Eye Disease Clinical Trials

A Randomized Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine

Start date: April 30, 2024
Phase: Phase 4
Study type: Interventional

The objective of this trial is to evaluate the effect of cyclosporine ophthalmic solution, 0.1% on corneal endothelial cell health in comparison to a hypotonic saline solution in subjects with Dry Eye Disease (DED)

NCT ID: NCT06323395 Completed - Dry Eye Disease Clinical Trials

Vizol S Lipid Balance Efficacy and Safety Study in Patients With Dry Eye

Start date: June 1, 2022
Phase: Phase 3
Study type: Interventional

The clinical investigation was intended to investigate the efficacy, ocular tolerability and safety of Vizol S Lipid Balance, a new eye drops, emulsion developed by JADRAN - GALENSKI LABORATORIJ d.d., in patients with moderate to severe evaporative DED after a treatment for 30 days.

NCT ID: NCT06317922 Recruiting - Dry Eye Syndromes Clinical Trials

Evaluation of Dry Eye Disease's Signs in Patients Who Were Administered Intravitreal Anti-VEGF Injections

DRYEYE-IVT
Start date: February 5, 2024
Phase: N/A
Study type: Interventional

The goal of this interventional, monocentric, prospective, single-masked, case-control study is to evaluate the efficacy of Thealoz Duo (artificial tear containing trehalose 3 g and hyaluronic acid 0.15 g) in comparison to a saline solution (Hydrabak containing Sodium Chloride 0,9 g, Sodium Dihydrogen Phosphate Dihydrate, Disodium Hydrogen Phosphate Dodecahydrate), to reduce the signs of ocular discomfort and ocular side effects in patients who have received Intravitreal injections. The main questions it aims to answer are: - can ocular instillation of Thealoz Duo solution, 1 week before intravitreal injection, in a fixed dose regimen, prevent ocular surface changes and dry-eye signs? - can ocular instillation of Thealoz Duo solution, up 3 months after intravitreal injections, in a fixed dose regimen, reduce ocular surface changes, and dry-eye signs with improvement of quality of life and quality of vision? Each participant will be randomized into each of two arms: 1. TREATMENT ARM: patients who will receive the instillation of Thealoz Duo, 10 ml, 1 drop, 4 times/day; 2. CONTROL ARM: patients who will receive the instillation of saline solution (Hydrabak), 10 ml, 1 drop, 4 times /day; The decision of inclusion of a control group should minimize the risk of breaking the blinding condition by affecting the consistency and reliability of the outcome's achievement. In any case, the instillation of saline solution should not alter the ocular surface.

NCT ID: NCT06309953 Recruiting - Dry Eye Clinical Trials

A Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

Start date: February 28, 2024
Phase: Phase 4
Study type: Interventional

An Open-Label, Multicenter, Phase 4 Study to Evaluate Early Treatment Outcomes With Miebo™ in Subjects With Dry Eye Disease

NCT ID: NCT06298890 Recruiting - Cataract Clinical Trials

The Pattern of Dry Eye Disease After Cataract Surgery

Start date: March 2024
Phase:
Study type: Observational

This study is designed to explore dry eye disease (DED) pattern: ocular surface, corneal morphological changes, patients' subjective assessment of DED and their correlations with ocular surface inflammation, pain biomarkers after cataract surgery according to ocular surface lubrication with artificial tears during long-term follow-up.

NCT ID: NCT06296966 Recruiting - Dry Eye Clinical Trials

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

Start date: February 29, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

NCT ID: NCT06291194 Recruiting - Dry Eye Syndromes Clinical Trials

Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients

Start date: November 10, 2023
Phase: Phase 3
Study type: Interventional

This study is planned to Evaluate the Efficacy and Safety of test drug (AJU-S56 5%) compared to control drug(vehicle) in Patients with Dry Eye Disease.

NCT ID: NCT06288945 Completed - Dry Eye Syndrome Clinical Trials

Effect of an Educational Program on Health-related Outcomes of Patients With Dry Eye Syndrome

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

Dry eye syndrome (DES) is a widespread ocular disease affecting the general population. It is a complex disorder affecting the surface of the eye, marked by an imbalance in the tear film and ocular symptoms. Therefore this study was done to determine the effect of an educational program on health-related outcomes of patients with DES including the severity of symptoms related to DES and their influence on visual-related functions